248. グルコーストランスポーター１欠損症
［臨床試験数：30，薬物数：9（DrugBank：1），標的遺伝子数：0，標的パスウェイ数：0］
Searched query = "Glucose transporter type 1 deficiency", "GLUT1 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04399954 (ClinicalTrials.gov) | February 24, 2020 | 18/5/2020 | Evaluation of Ketoflo | A Study to Evaluate the Acceptability of Ketoflo, a Food for Special Medical Purposes (FSMP) for Use in the Dietary Management of Epilepsy or Neurometabolic Conditions Requiring a Ketogenic Diet (KD) | Epilepsy Intractable;Glucose Transporter Type 1 Deficiency Syndrome;Ketogenic Dieting | Dietary Supplement: Ketoflo | Vitaflo International, Ltd | NULL | Recruiting | 3 Years | 18 Years | All | 15 | N/A | United Kingdom |
| 2 | NCT03773770 (ClinicalTrials.gov) | December 27, 2019 | 10/12/2018 | Expanded Access to Triheptanoin | An Open-label Intermediate-size Treatment Protocol for the Urgent Treatment of Seriously Ill Patients With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) With Triheptanoin (UX007) | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: Triheptanoin | Ultragenyx Pharmaceutical Inc | NULL | Available | N/A | N/A | All | NULL | ||
| 3 | NCT03301532 (ClinicalTrials.gov) | June 5, 2018 | 29/8/2017 | Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D | Compatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 Deficiency | GLUT1DS1 | Drug: Triheptanoin | University of Texas Southwestern Medical Center | National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 30 Months | 35 Years | All | 15 | Phase 2 | United States |
| 4 | NCT03202108 (ClinicalTrials.gov) | May 11, 2018 | 26/6/2017 | Evaluation of Krio in Children and Adults With Epilepsy | A Feasibility Study to Evaluate the Acceptability of Krio, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability | Ketogenic Dieting;Epilepsy;Glucose Transporter Type 1 Deficiency Syndrome | Dietary Supplement: Krio | Vitaflo International, Ltd | NULL | Withdrawn | 3 Years | N/A | All | 0 | N/A | United Kingdom |
| 5 | NCT03181399 (ClinicalTrials.gov) | April 18, 2018 | 25/4/2017 | Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) | Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D) | GLUT1DS1;Epilepsy;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency Syndrome | Drug: Triheptanoin | University of Texas Southwestern Medical Center | National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 24 Months | 35 Years | All | 45 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2015-000389-69-DK (EUCTR) | 23/08/2017 | 13/06/2017 | A trial to assess the long term safety and efficacy of UX007 in subjects who have already participated in a UX007 study. | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United States;Spain;Australia;Denmark;Israel;United Kingdom | |||
| 7 | EUCTR2015-005536-17-GB (EUCTR) | 04/08/2017 | 11/07/2017 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Australia;Israel;Germany;Italy;United Kingdom | |||
| 8 | EUCTR2015-005536-17-FR (EUCTR) | 30/06/2017 | 16/05/2017 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | United States;France;Spain;Ireland;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | |||
| 9 | EUCTR2013-003771-35-DK (EUCTR) | 07/06/2017 | 11/04/2017 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Australia;Denmark;Israel;Italy;United Kingdom | ||
| 10 | EUCTR2015-000389-69-ES (EUCTR) | 22/05/2017 | 27/03/2017 | A trial to assess the long term safety and efficacy of UX007 in subjects who have already participated in a UX007 study. | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 19.1;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Spain;Denmark;Australia;Israel;Italy;United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2015-005536-17-DE (EUCTR) | 17/05/2017 | 01/03/2017 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Australia;Israel;Germany;Italy;United Kingdom | |||
| 12 | NCT02960217 (ClinicalTrials.gov) | April 19, 2017 | 7/11/2016 | Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: UX007;Drug: Placebo | Ultragenyx Pharmaceutical Inc | NULL | Terminated | 6 Years | N/A | All | 44 | Phase 3 | United States;France;Germany;Italy;Spain;United Kingdom;Israel |
| 13 | NCT03041363 (ClinicalTrials.gov) | March 29, 2017 | 31/1/2017 | Treatment Development of Triheptanoin (G1D) | Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial | Epilepsy;GLUT1DS1;Glut1 Deficiency Syndrome 1, Autosomal Recessive;Glucose Metabolism Disorders;Glucose Transport Defect;Glucose Transporter Type 1 Deficiency Syndrome;Glucose Transporter Protein Type 1 Deficiency Syndrome | Drug: Triheptanoin | University of Texas Southwestern Medical Center | National Institute of Neurological Disorders and Stroke (NINDS) | Active, not recruiting | 2 Years | 35 Years | All | 36 | Phase 1 | United States |
| 14 | EUCTR2015-005536-17-ES (EUCTR) | 17/03/2017 | 10/03/2017 | A trial to assess the safety and efficacy of UX007 in patients with movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 19.1;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 3 | France;United States;Spain;Ireland;Australia;Israel;Netherlands;Germany;Italy;United Kingdom | |||
| 15 | NCT02968953 (ClinicalTrials.gov) | March 17, 2017 | 16/11/2016 | Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome | Treatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency Syndrome | Glucose Transporter 1 Deficiency Syndrome | Drug: Triheptanoin | Jerry Vockley, MD, PhD | Ultragenyx Pharmaceutical Inc | No longer available | 3 Years | N/A | Female | United States | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2015-000389-69-GB (EUCTR) | 27/01/2017 | 20/07/2016 | A trial to assess the long term safety and efficacy of UX007 in subjects who have already participated in a UX007 study. | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 20.0;Level: LLT;Classification code 10061032;Term: Carbohydrate transport disorder;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Denmark;Australia;Israel;Italy;United Kingdom | |||
| 17 | EUCTR2013-003771-35-HU (EUCTR) | 13/04/2016 | 10/08/2015 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 18.1;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN | Ultragenyx Pharmaceutical Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | France;United States;Hungary;Spain;Denmark;Australia;Israel;Italy;United Kingdom | |||
| 18 | NCT02915211 (ClinicalTrials.gov) | April 2016 | 19/9/2016 | Evaluation of Keyo in Children With Epilepsy | A Feasibility Study to Evaluate the Acceptability of Keyo, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability | Intractable Epilepsy;Glucose Transporter Type 1 Deficiency Syndrome;Ketogenic Dieting | Dietary Supplement: Keyo | Vitaflo International, Ltd | NULL | Completed | 3 Years | N/A | Both | 17 | N/A | United Kingdom |
| 19 | NCT02021526 (ClinicalTrials.gov) | December 2015 | 12/12/2013 | Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) | Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency | Glucose Transporter Type 1 Deficiency Syndrome;Glut1 Deficiency Syndrome | Drug: Triheptanoin | Juan Pascual | NULL | Withdrawn | 30 Months | 55 Years | All | 0 | Phase 1;Phase 2 | United States |
| 20 | EUCTR2013-003771-35-ES (EUCTR) | 19/11/2015 | 10/08/2015 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 18.0;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Triheptanoin / Triheptanoina Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Denmark;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02599961 (ClinicalTrials.gov) | September 10, 2015 | 3/11/2015 | Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) | An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 Deficiency Syndrome | Drug: UX007 | Ultragenyx Pharmaceutical Inc | NULL | Terminated | 1 Year | N/A | All | 15 | Phase 2 | United States;Australia;Denmark;Spain;United Kingdom |
| 22 | EUCTR2013-003771-35-GB (EUCTR) | 19/03/2015 | 10/11/2014 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 17.1;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;United States;Hungary;Spain;Denmark;Italy;United Kingdom | |||
| 23 | NCT02000960 (ClinicalTrials.gov) | April 2014 | 27/11/2013 | Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome | A Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome | Glucose Transporter Type 1 Deficiency Syndrome | Drug: Triheptanoin | University of British Columbia | Ultragenyx Pharmaceutical Inc | Active, not recruiting | 1 Year | 18 Years | Both | 3 | Phase 2 | Canada |
| 24 | NCT01993186 (ClinicalTrials.gov) | February 28, 2014 | 31/10/2013 | Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | Drug: UX007;Drug: Placebo | Ultragenyx Pharmaceutical Inc | NULL | Completed | 1 Year | 100 Years | All | 36 | Phase 2 | United States;Australia;France;Israel;Italy;Spain;United Kingdom;Hungary |
| 25 | EUCTR2013-003771-35-IT (EUCTR) | 11/02/2014 | 11/12/2013 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 14.1;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN | Ultragenyx Pharmaceutical Inc | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | France;United States;Hungary;Spain;Denmark;Netherlands;United Kingdom;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02036853 (ClinicalTrials.gov) | January 2014 | 13/1/2014 | An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome | An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS) | Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) | Drug: Triheptanoin | Adrian Lacy | Ultragenyx Pharmaceutical Inc | Recruiting | 1 Year | 50 Years | All | 50 | Phase 2 | United States |
| 27 | NCT02014883 (ClinicalTrials.gov) | December 2013 | 3/12/2013 | Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS | Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS | Glut1 Deficiency Syndrome | Drug: GLUT1 DS | Institut National de la Santé Et de la Recherche Médicale, France | Ultragenyx Pharmaceutical Inc | Recruiting | 3 Years | N/A | Both | 20 | Phase 2 | France |
| 28 | NCT02018302 (ClinicalTrials.gov) | October 2013 | 11/12/2013 | Post Study Continuation of C7 for G1D | Post Study Continuation of C7 for G1D | Glut1 Deficiency Syndrome;Glucose Transporter Type 1 Deficiency Syndrome | Drug: Triheptanoin | Juan Pascual | NULL | No longer available | 1 Month | 28 Years | All | United States | ||
| 29 | NCT02018315 (ClinicalTrials.gov) | January 2012 | 11/12/2013 | Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) | Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B) | Glucose Transporter Type 1 Deficiency Syndrome;GLUT1 Deficiency Syndrome | Drug: Triheptanoin | Juan Pascual | NULL | Completed | 1 Month | 20 Years | All | 14 | Phase 1 | United States |
| 30 | EUCTR2013-003771-35-FR (EUCTR) | 17/06/2015 | A trial to assess the safety and efficacy of UX007 in patients with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | Glucose Transporter Type 1 deficiency syndrome MedDRA version: 18.0;Level: HLGT;Classification code 10039911;Term: Seizures (incl subtypes);System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Triheptanoin Product Code: UX007 INN or Proposed INN: Not available Other descriptive name: TRIHEPTANOIN | Ultragenyx Pharmaceutical Inc | NULL | NA | Female: yes Male: yes | 80 | Phase 2 | United States;France;Hungary;Spain;Denmark;Italy;United Kingdom |